Pharma's big price gouge
After Martin Shkreli raised the price of anti-HIV drugDaraprim more than 50-fold to $US750 a pill, he said he wasn't alone in taking big price hikes.
After Martin Shkreli raised the price of anti-HIV drugDaraprim more than 50-fold to $US750 a pill, he said he wasn't alone in taking big price hikes.
Abbott has agreed to acquire Alere for an expected value of $US5.8 billion to enhance its diagnostics business.
Two months after private equity firm Archer Capital said it had sold Healthe Care to China's Luye Medical for $938 million the deal has yet to settle.
Investors in Nanosonics cheered a record sales result but at least one analyst has scaled back his expectations for a maiden profit.
Health Minister Sussan Ley's crackdown on health insurance premiums threatens the viability of smaller non-profit funds and may force industry consolidation.
Vitamins group Blackmores says it won't be in the running to buy smaller rival Nature's Care, which could fetch up to $1 billion in a trade ...
Despite two positive earnings surprises in less than six months, Medibank Private remains one of the most hated large-cap stocks on the ASX.
Goldman Sachs investment banker Adam Gregory is leaving the bank to set up an investment office backed by long-time client and vitamins comp...
Support for private health insurers has risen to its highest in two decades as not-for-profit funds threaten to campaign against reforms pla...
Healthcare offers the double whammy - a safe haven in times of volatility and a great growth profile - but the threat of government cuts is ...
Unlimited access to business news and market insights across any device
Already a subscriber? Log in